What it is
Retatrutide activates the receptors for three hormones: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon. In TRIUMPH-1, a phase 3, randomized, double-blind trial, 2,339 adults with obesity but without diabetes were assigned to a once-weekly injection under the skin of retatrutide (4 mg, 9 mg or 12 mg) or placebo for 80 weeks. Body weight fell by a mean of 17.6% with 4 mg, 23.7% with 9 mg and 25.0% with 12 mg, against 3.9% with placebo; for the 9-mg and 12-mg doses, the ones the primary outcomes compared with placebo, the differences were 19.8 and 21.0 percentage points (P<0.001 for both).
Why it matters
Besides a mean weight loss of up to 25.0% over 80 weeks, the trial's primary outcomes in two subgroups also improved. In the 574 participants with knee osteoarthritis, the 9-mg and 12-mg doses lowered the WOMAC pain score (1 to 10, higher meaning worse pain) by 1.4 and 1.6 points more than placebo, and in the 243 with obstructive sleep apnea they lowered the apnea-hypopnea index by 24.7 and 22.5 events per hour more than placebo (intention-to-treat results, reported alongside the main hybrid-estimand analysis; P<0.001 for each). The authors conclude that in adults with obesity, retatrutide resulted in significant weight reduction, reduced pain in those with knee osteoarthritis and reduced apnea-hypopnea events in those with obstructive sleep apnea.
Every metric behind this entry is listed, with its source, under Sources and data below.
Filed underPharmacology and Obesity Treatment, Diabetes Treatment and Management, Regulation of Appetite and Obesity
